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Abstract
Heart failure (HF) is multifactorial syndrome with high
cardiovascular (CV) morbidity and mortality rates associ‐
ated with an increasing prevalence worldwide. Measuring
plasma levels of circulating biomarkers, i.e., natriuretic
peptides, cardiac-specific troponins, metabolomic inter‐
mediates, Galectin-3, ST2, cardiotrophin-1, soluble endo‐
glin and growth differentiation factor 15, may assist in the
prognostication of HF development. However, the role of
biomarker models in the prediction of an early stage of HF
with a preserved ejection fraction (HFpEF) and HF with a
reduced ejection fraction (HFrEF) is not still understood.
This review explores the knowledge regarding the utility
of cardiac biomarkers, aiming to reclassify patients with
different phenotypes of HF. The review reports that several
biomarkers reflected on subsequently alter collagen
turnover, cardiac fibrosis and inflammation, which might
have diagnostic and predictive value in HFpEF and HFrEF.
The best candidates for determining the early stage of HF
development were sST2, Galectin-3, CT-1 and GDF-15.
However, increased plasma concentrations of these
biomarkers were not specific to a distinct disease group of
HFpEF and HFrEF. Finally, more investigations are
required to determine the role of novel biomarkers in the
prediction of HF and the determination of the early stages
of HFpEF and HFrEF development.
Keywords Heart Failure Phenotypes, Biomarkers, Prog‐
nostication, Risk Stratification
Abbreviations
BNP – brain natriuretic peptide
CAD – coronary artery disease
CABG – coronary artery bypass grafting
GDF – growth differentiation factor
CT-1 – cardiotrophin-1
CV – cardiovascular
HF – heart failure
HFpEF – heart failure with preserved ejection fraction
HFrEF – heart failure with reduced ejection fraction LV –
left ventricle
PCI – percutant coronary angioplasty procedure
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1. Introduction
Heart failure (HF) remains an important clinical entity that
has increased in prevalence worldwide due to improved
survival after a HF diagnosis [1, 2]. Recent studies have
shown sufficient differences in the aetiology, pathophysi‐
ology, clinical presentation and outcomes, as well as the
prognosis, between HF with a preserved ejection fraction
(HFpEF) and HF with a reduced ejection fraction (HFrEF)
[3-5].
HFpEF is  a phenotypic and heterogeneous clinical  syn‐
drome characterized by cardiovascular (CV) disease and
dysmetabolic and inflammatory states associated with both
advanced age and various non-CV co-morbidities, which
finally lead to the impairment of myocardial structure and
function, unless under the condition of declining global EF
<45% [6, 7]. Although global left ventricular EF >50% is
currently  used  to  differentiate  between  reduced  and
preserved cardiac pump function, this cut-off point is widely
discussed as a likely inadequate criterion [8, 9] However,
old age,  being female,  suffering from diabetes mellitus,
hypertension, atrial fibrillation and chronic kidney disease
are  strong  predictors  of  HFpEF’s  development  [10-12].
Based on evidence from endomyocardial biopsies, some of
the specific cardiac structural phenotypes to be targeted in
HFpEF may be represented by myocyte hypertrophy and
interstitial fibrosis [13, 14]. HFrEF has been described as a
disease  of  aged elderly  subjects,  with  a  male  predomi‐
nance that is frequently associated with dilation cardiomy‐
opathy, ischaemia, inflammatory and diabetic aetiology,
and rarely with arterial and pulmonary hypertension [15,
16].  Cell  loss  due to ischaemia,  apoptosis  and necrosis,
myocardial inflammation associated with oxidative stress,
expanded interstitial fibrosis leading to the disintegrity of
the cardiac wall, increased passive myocardial stiffness, the
worsening of cardiac configuration and contractile func‐
tion are common in HFrEF’s development [17].
Many questions remain unanswered regarding differences
in the molecular signals that initiate the development of
HFpEF and HFrEF [18]. In this context, it might be possible
to appropriately stratify at risk HFpEF and HFrEF patients
by using biomarkers. Recently, brain natriuretic peptides,
cardiac specific troponins, metabolomic intermediates,
Galectin-3, ST2, cardiotrophin-1, soluble endoglin, growth
differentiation factor 15 and other new biological markers
associated with HF’s development have been widely
investigated [5, 6, 12, 13, 17, 19]. However, the current data
on the interrelationship of these biomarkers and pheno‐
types of HF are limited. The aim of the review is devoted
to the accumulation of knowledge regarding the utility of
cardiac biomarkers, aiming to reclassify patients with
different phenotypes of HF.
2. Biomarkers in HF Risk Stratification
The routine use of biomarkers might help to stratify the
patients with HFrEF and HFpEF at higher risk of death and
clinical outcomes. The current guidelines — the 2012
European Society of Cardiology (ESC) Guidelines for the
Diagnosis and Treatment of Acute and Chronic Heart
Failure and the 2013 American College of Cardiology
Foundation/American Heart Association (ACCF/AHA)
Guideline for the Management of Heart Failure — are well
accepted by many clinicians regarding HFrEF’s prognosti‐
cation. Indeed, HFpEF is the one that really requires the
improvement of biomarkers for diagnosis and prognosis.
In this context, many biological markers, which reflect
several faces of the pathogenesis of HF, have been investi‐
gated in detail, but only natriuretic peptides, soluble ST2,
Galectin-3 and highly sensitive cardiac-specific troponins
have been validated thus far. Table 1 offers summarized
evidence regarding the predictive role of biomarkers in
patients with different HF phenotypes.
3. Brain Natriuretic Peptides
Within the last two decades, cardiac natriuretic peptides
(BNP and NT-proBNP) have been defined as biomarkers
that we may use to screen for LV systolic dysfunction in
patients with symptoms suggestive of HF. BNP and NT-
proBNP are now included in the current guidelines for HF
diagnosis, management and risk assessment because of
their high specificity and sensitivity [19]. Despite BNP and
NT-proBNP improving discrimination modestly for HF
above and beyond conventional risk factors, and substan‐
tially improving the risk classification for HF, peak con‐
centrations of BNP and NT-proBNP and serial
measurements of NT-proBNP levels in longitude are not
able to allow the differentiation of HF phenotypes [20, 21].
However, there were important differences in the prog‐
nostic value of NT-proBNP in HFpEF versus HFrEF in the
NT- proBNP-guided arm of the TIME-CHF study [22]. NT-
proBNP has demonstrated less prognostic value in HFpEF
as compared to HFrEF, and has not predicted a develop‐
ment of HFpEF or HFrEF. NT-proBNP lost significance as
a risk stratifier in ambulatory patients with stable HF and
probably also in those who have HFpEF. There are attampts
to use of sing sample measurement of mid-regional atrial
natriuretic peptide (mr-ANP) and NT-proANP in order to
screen HFpEF and HFrEF in individuals, when the diag‐
nosis of HF is not obvious. In this setting, the diagnostic
value and prognostic ability for HF-related mortality and
CV hospitalization for both mr-ANP and NT-proANP were
not superior to those of NT-proBNP [23].
4. Cardiac Troponins
Recent studies have shown that elevated levels of highly
sensitive cardiac troponin I (hs-cTnI) and T (hs-cTnT) as
biomarkers of subclinical myocardial injury may provide
to be clinically useful prognostic information, concerning
both the future risk of HF’s manifestation in asymptomatic
subjects and the risk of fatal events and primary/re-
admissions in the hospital in those with already established
symptomatic acute, acutely decompensated and chronic
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stable HF related to ischaemic and non-ischaemic causes
[24-27]. Moreover, cardiac troponin mutations are consid‐
ered a cause of impaired relaxation in the mutant cardiac
myocytes due to myofibril hypersensitivity to Ca2+ [28].
Cardiac-specific troponins exhibited the strongest associa‐
tions with hospitalization, survival and outcomes in cases
of HF; there are expectations regarding the ability of
troponins to emerge as an aetiology-dependent relation to
phenotypes of HF. Seliger et al. [29] hypothesized that hs-
cTnT would identify HF risk among older adults with left
ventricular hypertrophy (LVH). In the Cardiovascular
Health Study, its authors found that the adjusted risk of
HFrEF was 7.8 times higher among those with the highest
tertile of hs-cTnT and LVH (HR=7.83; 95% CI: 4.43-13.83).
Patients with LVH and longitudinal increases in hs-cTnT
or NT-proBNP were approximately three times more likely
to develop HF (primarily HFrEF), compared with those
without LVH and with stable biomarkers. Thus, in this
study, the authors were not able to find sufficient advan‐
tages regarding hs-cTnT compared NT-proBNP in order to
characterize sub-phenotypes of HF. In another study,
Neeland et al. [30] reported that identifying a malignant
sub-phenotype of LVH was the better predictive surrogate
marker than a limited elevated level of hs-cTnT, and even
increased NT-proBNP among asymptomatic individuals
with a high risk of progression to HF and CV death in the
general population. Therefore, there was evidence that the
higher levels of cTnT and NT-proBNP correlated well with
the risk of HF in older adults, but were not associated with
phenotypes of HF [31]. Overall, the circulating level of the
cell injury biomarker is not a powerful tool for HF-pheno‐
type detection.
5. Systematic Metabolomic Biomarkers
Zordoky et al. [32] suggested that a systematic metabolo‐
mic analysis would reveal a novel metabolomic fingerprint
of HFpEF that will help us to understand its pathophysiol‐
ogy and assist us in establishing new biomarkers for its
diagnosis. Compared to non-HF control, HFpEF patients
demonstrated higher serum concentrations of acylcarni‐
tines, carnitine, creatinine, betaine and amino acids, and
lower levels of phosphatidylcholines, lysophosphatidyl‐
cholines and sphingomyelins. Medium- and long-chain
acylcarnitines and ketone bodies were higher in HFpEF
than in HFrEF patients. The authors suggested that this
abovementioned metabolomic fingerprint has been
utilized to identify two novel panels of metabolites that can
separate HFpEF patients from both non-HF controls and
HFrEF patients. However, this assumption requires further
investigation.
Biomarkers Patient population The most important findings References
Natriuretic peptides Exerted dyspnoea Predictor of HF risk manifestation, risk of admission in
the hospital and HF-related deaths
[19]
Known HFpEF and HFrEF Biomarkers independently predicted HF-related
outcomes, CV mortality, all-cause death, admission in
the hospital, but they did not predict a development of
HFpEF or HFrEF
[19, 20, 21]
Cardiac troponins Ischaemia-induced HF Predictors of HF manifestation risk in asymptomatic
subjects




Predictors of death, primary/re-admissions in the
hospital
[25-27]
Galectin-3 General population Prognosticator of HF risk, risk of death from any cause [33]
Known HF patients Predictor of CV death, HF-related deaths, primary and
re-admission in the hospital
[35-37]
Soluble ST2 General population Predictor of higher risk of all-cause mortality, HF
manifestation
[42]
Known HF patients Independent predictor of CV deaths, HF-related deaths,
admission in the hospital
[44]
Cardiotrophin-1 Known ischaemia-induced HF
patients
Predictor of CV clinical outcomes [53, 54]
Endoglin Patients at higher risk of CV disease Predictor of CV events/ outcomes, HF manifestation [58-60]
Growth differentiation factor 15 Patients with known CV disease Predictor of HF manifestation [64, 65]
Known HF patients Predictor of HF-related outcomes [68]
Abbreviation: CV, cardiovascular; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.
Table 1. Predictive role of biomarkers in patients with different HF phenotypes
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5.1 Galectin-3
It has been suggested that various alternative biomarkers
might offer insight into the different pathways of HF’s
pathophysiology, and that they might help to identify
individuals in the general population at higher risk of
developing HF and patients with known chronic HF with
poor outcomes [33]. Galectin-3 is a soluble beta galactoside-
binding lectin produced by activated macrophages that
bind and activate the fibroblasts [34]. Currently, Galectin-3
is considered a biomarker that mediates an important link
between inflammation and fibrosis, which plays a pivotal
role in CV remodelling. The pathogenetic role of Galectin-3
in the various settings of pressure overload, neuro-
endocrine activation, hypertension, coronary artery
disease/myocardial infarction, atrial fibrillation and HF has
been established.
Galectin-3 has emerged as a predictive value for the onset
of HF in apparently healthy patients and has been found to
be a surrogate marker of a worse prognosis, mortality and
re-admission in HF [35, 36]. However, serial measurements
of Galectin-3 levels in ambulatory HF patients might not be
of benefit [37].
In the context of determining the different phenotypes of
HF, the measurement of circulating Galectin-3 might have
a significant value because elevated levels of Galectin-3
were found in patients with impaired LV diastolic function,
but without symptomatic HF [38]. Gurel et al. [39] reported
that Galectin-3 could be a promising biomarker for the
detection of LV diastolic dysfunction in patients undergo‐
ing maintenance haemodialysis. It has been suggested that
this biomarker could be a useful surrogate for structural
and functional abnormality of the myocardium among
individuals at higher risk of HFpEF development, espe‐
cially that associated with hypertension, coronary artery
disease and diabetes [40, 41]. However, there is no irrefut‐
able evidence regarding the clinically significant advan‐
tages of Galectin-3 in predicting HFpEF’s evolution
compared with HFrEF’s development.
5.2 ST2
Soluble ST2 (sST2), a peptide belonging to the interleukin-1
receptor family, is secreted by cardiomyocytes and cardiac
fibroblasts under mechanical strain, and is thus regarded
as a biomarker of myocardial fibrosis, cardiac stretching
and CV remodelling [42, 43]. Measurement of sST2 levels
is useful for death risk stratification and prognosis predic‐
tion in HF patients, beyond other CV risk factors [44]. The
sST2 concentration showed a weak correlation with the
NYHA functional class, LFEF, other cardiac performances
and renal function [45, 46]. Recent studies have shown that
sST2 may have a special superiority as a risk predictor in
HFpEF and HFrEF as compared with natriuretic peptides
and Galectin-3 [47, 48]. However, there are no current data
on the predictive value of sST2 concentrations for HFpEF
or HFrEF development.
5.3 Cardiotrophin-1
Cardiotrophin-1 (CT-1) is a member of the interleukin 6
cytokine superfamily and one of the endogenous ligands
for gp130 signalling pathways in the heart, with controver‐
sial biological effects. CT-1 is able to induce hypertrophic
growth and contractile dysfunction in cardiomyocytes, as
well as having potent hypertrophic and survival effects on
cardiac myocytes [49]. CT-1 is closely associated with many
CV diseases, i.e., hypertension, myocardial infarction and
HF, and exhibits a cardioprotective effect in ischaemia-
reperfusion injury during CABG and angioplasty [50].
Recent clinical studies have shown that CT-1 levels are
increased in HF patients, and that it is significantly corre‐
lated with the LV mass index, suggesting that CT-1 plays
an important role in structural LV remodelling [51, 52].
Increased cardiotrophin-1 plasma levels might predict the
presence of an inappropriate LV mass merge in hyperten‐
sive subjects [53], and the development and progression of
HF [54]. Moreover, CT-1 is elevated in patients with HFpEF
and is associated with NT-proBNP and estimated LV filling
pressures [55]. Whether increased serum CT-1 may provide
additional information to aid risk stratification in the
development of HFrEF or HFpEF is not completely clear.
5.4 Soluble endoglin
Endoglin (also known as CD105) is a membrane co-receptor
for transforming growth factor-β, which is released into the
circulation in a soluble form and which disrupts TGFβ1
signalling in the endothelium, thereby promoting inflam‐
mation, endothelial dysfunction, cardiac fibrosis and
vascular remodelling [56, 57]. Endoglin is required for
vascular barrier function, endothelial survival and homeo‐
stasis of the adult microvasculature, although endoglin is
expressed in cardiac fibroblasts and may modulate profi‐
brogenic actions of angiotensin II [58]. A recent clinical
study has revealed that the expression of endoglin is
increased in patients with atherosclerosis and that the
endoglin level is thought to predict CV events in patients
with chronic coronary artery disease after PCI [59]. There
is evidence regarding the predictive role of elevated serum
endoglin in patients with pre-eclampsia [60]. In patients
with HFrEF, elevated soluble endoglin levels predicted
elevated LV end-diastolic pressures, and correlated well
with the New York Heart Association class, irrespective of
LVEF, as well as with both atrial and brain natriuretic
peptides [56, 61]. The ability of soluble endoglin in predic‐
tion of HFpEF and HFrEF is not understood, while there
are expectations regarding the role of this biomarker for
prognostication in LV dysfunction at early onset. However,
extended scrutiny is required to receive more information
for testing this assumption.
5.5 Growth differentiation factor 15
Growth  differentiation  factor  15  (GDF-15)  is  a  stress-
responsive cytokine, which belongs to the super family of
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the transforming growth factor beta [62]. GDF-15 is widely
presented in the wide spectrum of various cells and plays
a pivotal role in inflammation, cell growth and differentia‐
tion.  Elevated  GDF-15  was  found  in  patients  with
established  CV  diseases  (hypertension,  stable  coronary
artery  disease,  acute  coronary  syndrome,  myocardial
infarction, ischaemic and non-ischaemic-induced cardio‐
myopathies,  HF,  atrial  fibrillation),  type-two  diabetes
mellitus, chronic renal disease, infection and liver cirrho‐
sis and malignancy [63].
Recent studies have revealed that GDF-15 was associated
with the NYHA class, NT-proBNP and exercise capacity,
suggesting that the marker has diagnostic and potentially
prognostic value in HF [64-66]. It has been suggested that
GDF-15 might categorize HFrEF and predict major HF-
related clinical outcomes [67]. Chan et al. [68] reported that
the plasma levels of GDF15 in HFpEF and HFrEF were
similar. Therefore, there was an independent verification
of the prognostic utility of GDF15 in HFrEF and HFrEF. The
authors have shown that GDF15 was a significant inde‐
pendent predictor for composite outcome, even after
adjusting for important clinical predictors including hsTnT
and NT-proBNP [68]. Overall, GDF15 was not able to assist
in detecting the early stage of HFpEF, and this biomarker
has produced very limited evidence regarding the deter‐
mination of diastolic dysfunction.
6. Conclusion
Several reports have shown that biomarkers reflecting the
differentiation of fibroblasts into myofibroblasts, subse‐
quently altering collagen turnover, cardiac fibrosis and
inflammation, might have diagnostic and predictive value
in HFpEF and HFrEF. The biomarkers with most predictive
value in determining the early stage of HF’s development
were sST2, Galectin-3, CT-1 and GDF-15. However,
increased plasma concentrations of these biomarkers were
not specific for a distinct disease group of HFpEF and
HFrEF. Finally, more investigations are required to
determine the role of novel biomarkers in predicting HF
and the determination of the early stage of HFpEF and
HFrEF’s development.
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